Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Dalac

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
The American Journal of Surgical Pathology|October 20, 1998
Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 casesB Vergier, M Beylot-Barry, K Pulford, et al.
International Journal of Cancer|June 22, 2000
Delays in diagnosis and melanoma prognosis (I): the role of patientsM A Richard, J J Grob, M F Avril, et al.
International Journal of Cancer|June 22, 2000
Delays in diagnosis and melanoma prognosis (II): the role of doctorsM A Richard, J J Grob, M F Avril, et al.
Archives of Dermatology|March 23, 1999
Melanoma and tumor thickness: challenges of early diagnosisM A Richard, J J Grob, M F Avril, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2011
Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized studyT Jouary, C Leyral, B Dreno, et al.
The British Journal of Dermatology|July 8, 2015
Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study GroupC Hurabielle, S Ingen-Housz-Oro, N Ortonne, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 18, 2023
Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life studyK Khelef, E Maubec, G Jeudy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2021
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data<sup>☆</sup>Y Di Filippo, S Dalle, L Mortier, et al.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2018
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM Kandel, C Allayous, S Dalle, et al.
Annales De Dermatologie Et De Venereologie|September 5, 2025
Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel)F Skowron, S Mouret, A Seigneurin, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
The American Journal of Surgical Pathology|October 20, 1998
Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 casesB Vergier, M Beylot-Barry, K Pulford, et al.
International Journal of Cancer|June 22, 2000
Delays in diagnosis and melanoma prognosis (I): the role of patientsM A Richard, J J Grob, M F Avril, et al.
International Journal of Cancer|June 22, 2000
Delays in diagnosis and melanoma prognosis (II): the role of doctorsM A Richard, J J Grob, M F Avril, et al.
Archives of Dermatology|March 23, 1999
Melanoma and tumor thickness: challenges of early diagnosisM A Richard, J J Grob, M F Avril, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2011
Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized studyT Jouary, C Leyral, B Dreno, et al.
The British Journal of Dermatology|July 8, 2015
Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study GroupC Hurabielle, S Ingen-Housz-Oro, N Ortonne, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 18, 2023
Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life studyK Khelef, E Maubec, G Jeudy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2021
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data<sup>☆</sup>Y Di Filippo, S Dalle, L Mortier, et al.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2018
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM Kandel, C Allayous, S Dalle, et al.
Annales De Dermatologie Et De Venereologie|September 5, 2025
Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel)F Skowron, S Mouret, A Seigneurin, et al.
Pageof 11